Psychiatric aspects of tumours of the central nervous system by Madeira, N et al.
rEViEW ArtiCLE
Psychiatric aspects of tumours of the central nervous system
NUNO MADEIRA* 
PEDRO OLIVEIRA 
Psychiatry Department, Centro Hospitalar e Universitário de Coimbra; Faculty of Medicine, University of Coimbra
TIAGO SANTOS
Department of Psychiatry and Mental Health, Baixo Vouga Hospital Centre
EMíLIA ALBUqUERqUE
Psychiatry Unit, Francisco Gentil Portuguese Institute of Oncology, Coimbra
Abstract: The incidence of brain tumours has increased in recent years. They represent the second most common cause 
of death attributable to neurological conditions. Although expansive brain lesions often lead to observation by Neurology 
or Neurosurgery, it is not uncommon for psychiatric symptoms to be the reason for initial contact with medical care. Brain 
tumours may present as symptomatology similar to the so-called primary, or functional, psychiatric disorders. However, 
in contrast to psychiatric disease in other types of cancer, where adjustment disorders predominate, organic syndromes 
are the most frequent diagnosis in patients with CNS tumours.
Anatomic location represents one of several factors that contribute to the nature and severity of psychiatric conditions. 
Tumours of the frontal lobe are more frequently associated with changes in executive function, amotivational syndrome 
and personality changes. Temporal tumours can trigger psychotic symptoms such as hallucinations and delusions.
The treatment of the symptomatology will essentially involve removal of the lesion whenever possible. Nevertheless, 
symptomatic treatment of psychiatric manifestations should always take place. Psychopharmacology, psychotherapy and 
psychoeducation of caregivers are the best modes of treatment.
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introduction
Psycho-oncology spans the two principal psychiatric and 
psychological dimensions of cancer: on the one hand, the 
experiences of patients and their family members over the 
course of the disease, and also the stress felt by care-giv-
ing professionals; on the other, the psychological, behav-
ioural and social factors that influence risk, detection and 
survival of oncological disease 1 . 
The incidence of brain tumours has increased in recent years. 
They represent the second most common cause of death at-
tributable to neurological causes, the first being stroke 2 .
Brain tumours can be classified according to their nature 
(primary or metastatic), histology or location. Gliomas 
(40-55%) and meningiomas (10-20%) represent the ma-
jority of expansive intracerebral lesions. Metastatic le-
sions (15-25%) originate most commonly from lung and 
breast tumours. 30% of tumours are located in the poste-
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rior fossa, the most common supratentorial lesions being 
those of the frontal (22%) and temporal lobes (22%); 12% 
are located in the parietal lobes, 10% in the sella turcica, 
and 4% in the occipital cortex 2 .
Cerebral metastases generally manifest as hemiparesis 
and cognitive dysfunction; unilateral hypoesthesia, atax-
ia and aphasia are less common symptoms 3 . The usual 
symptomatology of primary brain tumours – solid tu-
mours or lymphomas – is cognitive dysfunction, head-
aches, vomiting, seizures and focal deficits 4 . Disease 
progression and the toxic effects of treatment (e.g. radio-
therapy) tend to cause cognitive deterioration to worsen 
and, at advanced stages, demential syndromes or changes 
in consciousness.
While expansive brain lesions often lead to observation by 
Neurology or Neurosurgery, it is not uncommon for initial 
contact with medical care to be prompted by psychiatric 
symptoms. A study of 530 patients with brain tumours re-
ported that in 18% of cases clinical presentation was psy-
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chiatric 5 . A recent analysis of patients with meningiomas 
indicated that 21% of the study sample had initially pre-
sented with psychiatric symptoms in the absence of neu-
rological signs 6 .
Clinical Aspects
Brain tumours may present in the form of symptoms 
similar to primary, or functional, psychiatric disorders. 
However, in contrast with what happens with regard to 
psychiatric illness in other types of cancer, where ad-
justment disorders predominate, organic syndromes are 
the most common diagnosis in patients with tumours of 
the CNS.
Although some symptoms or syndromes may be associ-
ated with dysfunction of certain parts of the brain (e.g. 
depression and personality changes in frontal tumours and 
psychosis in temporal lesions), anatomic location repre-
sents one of several factors that contribute to the nature 
and severity of the psychiatric picture. Fast-growing tu-
mours are more frequently associated with agitation and 
psychosis, and more obvious cognitive dysfunction. Less 
aggressive lesions are associated with apathy, depression 
and incomplete personality changes. Multiple tumour sites 
tend to cause more significant behavioural changes. In-
creased intracranial pressure, a non-specific consequence 
of tumours of the CNS, is associated with apathy, depres-
sion, irritability, agitation and changes of consciousness.
Silent onset and few symptoms are a feature of the evo-
lution of tumours of certain regions of the brain; lesions 
of the anterior part of the frontal lobes, the corpus callo-
sum, the non-dominant parietal and temporal cortex and 
the posterior fossa are examples of this 2 .
Frontal Lesions 
The frontal lobe constitutes the most recently evolved re-
gion of the brain in phylogenetic terms and the largest in 
the central nervous system, representing 1/3 of its total 
volume. From the anatomo-functional point of view, the 
frontal lobe is divided into at least five specialised regions: 
(1) motor cortex, (2) pre-motor cortex, (3) frontal opercu-
lum, (4) para-olfactory or subcallosal zone and (5) pre-
frontal cortex. The pre-frontal cortex is the region of the 
frontal lobe most commonly related to metacognitive abil-
ities, executive functions and social behaviour in general. 
It can be divided into three distinct zones, which corre-
spond to the dorsolateral, orbitofrontal and frontomedial 
cortex. In general terms, we can organise the nature of the 
deficits resulting from lesions in accordance with the pro-
posed division of the pre-frontal cortex by establishing the 
existence of three syndromes – see Table 1. 7
dorsolateral, or disorganised, syndrome, characterised 
by impairment of executive functions, is due in the major-
ity of cases to tumour lesions, ischaemic lesions, trauma 
or neurodegenerative disease of the frontal lobe 8 . Ventro-
medial syndrome, which manifests above all as apathy, 
is usually related to tumour lesions of midline structures 
(thalamus, third ventricle, hypothalamus and pituitary), 
and also occurs following bilateral occlusion of the ante-
rior cerebral arteries and bilateral thalamic infarcts. Lastly, 
orbitofrontal syndrome, in which changes in behaviour 
and pragmatics are to the fore, is associated with tumours 
(e.g. inferior frontal meningiomas), as well as post-trau-
matic lesions, vascular lesions of the anterior cerebral ar-
tery, multiple sclerosis and fronto-temporal dementia 8 .
Table 1. Frontal syndromes
dOrSOLAtErAL syndrome 
Predominant involvement of executive functions.
Poor planning 






Behaviours directed at stimuli 
VENtrOMEdiAL syndrome 






Predominance of personality changes.







This anatomo-functional division is rarely clear in clin-
ical practice: pure presentations of these syndromes are 
uncommon. In addition, personality changes, particular-
ly associated with frontal lesions (more than 70% of cas-
es), may occur in disorders of diencephalic and temporal 
structures. 
Psychotic symptoms may be present in 10% of frontal tu-
mours. Delusions are usually fragmented and hallucina-
tions are rarely auditory and complex, in contrast to what 
is most characteristic of schizophrenic psychosis 2 .
temporal lesions
In addition to frequent symptoms of the ictal sphere, tu-
mours of the temporal region have in the past been associ-
ated with psychotic symptoms of a schizophreniform type. 
However, more recent reports have described atypical 
symptoms, not always associated with schizophrenia: vis-
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ual, olfactory or tactile hallucinations, and mood swings 
with suicidal behaviours, with conserved affect and social 
interaction.
Behavioural symptoms are common in temporal lesions: 
personality changes have been described in more than 
50% of patients. As described in lesions of the frontal 
lobe, psychiatric symptoms like apathy, irritability and 
emotional lability occur. Anxiety is also present in more 
than 30% of cases 2 .
Parietal and occipital lesions 
Lesions of the parietal or occipital cortex have been as-
sociated with psychiatric symptoms to a lesser degree. 
Parietal lesions are usually associated with perceptual and 
motor impairments, such as astereognosis and agraphes-
thesia, apraxia, anosognosia, acalculia and dysgraphia 9 .
25% of patients with occipital tumours present visual 
hallucinations – generally simple, e.g. luminous flashes. 
Other symptoms that have been reported – agitation, irri-
tability, drowsiness – probably reflect non-specific man-
ifestations of intracranial hypertension. In addition to 
typical findings like homonymous hemianopia, visual ag-
nosia and prosopagnosia are also common 2 .
Lesions of other structures 
Diencephalic tumours often compromise structures con-
tiguous with the limbic system; it is also common for 
cortico-subcortical circuits to be affected, with subse-
quent psychiatric manifestations. Schizophreniform 10 , 
affective 11 and obsessive-compulsive type symptoms 12 
and personality changes 13 have been reported. Behav-
ioural changes are usual in lesions of the corpus callo-
sum (especially genu and splenium), with an estimated 
prevalence of 90%. Affective symptoms predominate; 
personality changes and psychotic symptoms are also 
common 2 . Tumour lesions of the hypothalamus have 
been associated with changes of eating behaviour, in 
particular hyperphagia; clinical observations compatible 
with a diagnosis of anorexia nervosa have also been re-
ported in the literature 14 . Subcortical tumours may pre-
sent with a predominance of memory deficits, possibly 
within the framework of a subcortical-type demential 
syndrome 2 .
delirium
The clinical appearance of delirium includes: prodromal 
manifestations (restlessness, anxiety, insomnia and irri-
tability); fluctuating evolution; distractibility; changes in 
state of wakefulness; disruption of sleep-wake rhythm; 
affective symptoms (emotional lability, sadness, distress, 
euphoria); sensoriperceptual changes (illusions, visual and 
auditory hallucinations); paranoid delusions; disorganised 
speech; temporo-spatial and autopsychic disorientation; 
memory impairments (especially of short-term memory). 
Onset of symptoms is acute or subacute, and the latter are 
transient and reversible. These chronological characteris-
tics help differentiate it from demential syndrome. In their 
early stages, cases of hypoactive delirium may be inter-
preted as depression. In rare situations, delirium may be the 
initial manifestation of neoplastic lesions in the CNS 15 .
The approach to delirium includes from the start identify-
ing and correcting, wherever possible, underlying causes 
(see Table 2). 
Table 2. Causes of delirium in the oncological patient
Direct brain injury Primary brain tumour, cerebral 
metastasis
Metabolic encephalopa-
thy due to organ failure 




Sodium, potassium, calcium, 
glucose









Anaemia (microcytic, macrocytic), 
coagulopathy
Nutrition Malnutrition, ↓thiamine, ↓folic 
acid or ↓vitamin B12
Other Pain, constipation, paraneoplastic 
syndromes 
(Adapted from Breitbart and Cohen, 1998)
Support measures may be sufficient, in particular environ-
mental optimisation: quiet rooms with soft lighting, with 
personal objects and chronological references (clock, cal-
endar). The presence of family members may prove par-
ticularly calming. In the case of prior sensory dysfunction 
requiring visual or auditory prostheses, especially in the 
elderly, these should be available at all times. Physical 
restraint, for the patient’s protection, may be used judi-
ciously.
Support measures often prove insufficient, rendering 
pharmacological intervention necessary. Neuroleptics, as 
dopaminergic antagonists, are the drugs of choice in symp-
tomatic control of delirium (see Table 3).
Table 3. Pharmacotherapy of delirium in oncology
Posology routes of administration
Haloperidol 1-5 mg, every 2-12h PO, IM, IV
Chlorpromazine 25-100 mg, every 4-12h PO, IM, IV
Risperidone 1-3 mg, every 12h PO, Orodisp.
Olanzapine 2.5-10 mg every 12h Orodisp.
Quetiapine 25-100 mg, every 8h PO
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Parenteral doses are approximately twice as potent as oral 
doses and have more rapid onset of action. Pharmacologi-
cal intervention should be particularly scrupulous in ter-
minal patients, and reserved for situations of psychomotor 
agitation, hallucinations and paranoid delusions.
Dementia and cognitive deficit
In dementia the emergence of the picture is insidious or 
subacute, in contrast to delirium, from which it is further 
differentiated by the absence of changes of consciousness 
and by lesser disruption of sleep-wake rhythm.
Neurological and cognitive deficits attributable to tumour 
lesions of the CNS may be focal or global. While the for-
mer are associated with direct injury – tumoural or by ra-
diation – to specific regions, global deficits are generally 
the consequence of diffuse effects (intracranial hyperten-
sion and oedema), attributable to the tumour or to treat-
ments in progress, particularly radiotherapy (Table 4). 
In addition to acute (e.g. oedema) and semi-acute reac-
tions (e.g. demyelination), radiotherapy of brain tissue 
may give rise to late reactions of the encephalopathic 
type, which occur in approximately 28% of patients 16 and 
are potentially fatal or irreversible. Demential syndromes 
that arise after radiotherapy are of the subcortical type and 
ataxia and urinary incontinence are common; the estimat-
ed frequency is 3% 17 .
Table 4. Post-radiotherapy organic mental syndromes
Onset Symptoms Cause Evolution
Acute Immediate Lethargy, headache, fever, nausea/vomiting ↑ Intracranial pressure
Early 6 to 16 weeks Lethargy, headache, fever, nausea/vomiting, 





Late > 6 months Focal neurological ss., headache, 
personality changes, seizures
Encephalopathy? Severe and permanent
The impact of chemotherapy in cognitive terms, possibly 
underestimated if compared with the profusion of research 
into the effects of radiotherapy, has been highlighted re-
cently. The review of neurotoxic effects of chemother-
apy agents has described a variety of syndromes, such 
as central and peripheral neuropathies, encephalopathy, 
leukoencephalopathy, ototoxicity and cerebellar symp-
toms 9 . Even so, available information on the cognitive 
effects of chemotherapy is limited.
Neuropsychological studies in patients with tumours of 
the CNS have shown more pronounced deficits in pa-
tients with fast-growing lesions, namely glioblastoma 
multiforme and grade III or IV astrocytomas 18 . The later-
ality of lesions has also been shown to have a functional 
impact, lesions on the left being associated predomi-
nantly with worse results in verbal tests, while lesions 
of the right hemisphere are more damaging in tests 
of performance.
Mood disorders and anxiety 
Depressive and anxiety syndromes are common in this 
population. By comparison with so-called ‘function-
al’ forms, patients with tumours of the CNS also show 
cognitive deficits that are sometimes subtle, and psycho-
therapeutic interventions are more difficult. In pharma-
cological terms, some specificities must also be noted; 
benzodiazepines can have paradoxical effects in these pa-
tients: low-dose antipsychotics are a viable alternative.
Corticotherapy, often administered at high doses, repre-
sents a frequent cause of affective symptoms, and psy-
chotic conditions are also described 4 . Other common 
causes of anxiety and depression in oncological patients 
are set out below, in Tables 5 and 6 respectively.
Table 5. Causes of Anxiety in the oncological patient
SITUATIONAL – Communication of diagnosis, 
discussion of prognosis 
– Crisis related to disease or treatment 
– Conflict with family member or 
professional
– Anticipation of a frightening 
procedure 
– Waiting for results of supplementary 
examinations 
– Fear of recurrence 
DISEASE-
related 
– Uncontrolled pain 
– Metabolic disturbances
– Functional endocrine tumours 
– Paraneoplastic syndromes 
TREATMENT-
related
– Frightening (e.g. MRI) or painful 
procedures 
– Anxiogenic drugs (bronchodilators, 
antiemetics)
– Withdrawal states (opioids, 
benzodiazepines, alcohol)





– Phobia (blood, needles, 
claustrophobia)
– Panic disorder or generalised 
anxiety disorder 
– Post traumatic stress disorder 
– Obsessive-compulsive disorder
(Adapted from Holland & Stiles, 2009)
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Table 6. Risk factors for depression  




• IFN and IL-2
• Chemotherapy agents (vincristine, vinblastine, 
procarbazine, L-asparaginase)
• Others: propanolol, tamoxifen, phenobarbital
– Metabolic disturbances
• Anaemia, hypercalcaemia, ↓vit. B12, ↓folic acid
– Endocrine disturbances
• Hypothyroidism (++), hyperthyroidism (-)
• Adrenal insufficiency
– Paraneoplastic syndrome 
(Adapted from Holland & Stiles, 2009)
Psychopharmacology
The available information on the use of psychopharmaceu-
ticals in oncological patients comes above all from the clini-
cal experience of liaison psychiatry teams, in the form of 
isolated reports or small series, and not controlled trials.
The usual approach is use of small doses ab initio, with 
a preference for drugs that have a short half-life and no 
metabolites.
Antipsychotics are particularly useful in situations of de-
lirium, and in organic syndromes with behavioural chang-
es. The detrimental effect on the seizure threshold should 
be taken into consideration, especially in the class of the 
phenothiazines (levomepromazine, chlorpromazine). Ex-
trapyramidal symptoms, in particular akathisia, may oc-
cur, especially in patients also medicated with antiemetics 
like metoclopramide.
As regards the prescription of antidepressants (Table 7), 
selective serotonin reuptake inhibitors (SSRIs) represent 
a safe and well tolerated class of drugs. Their potential 
for pharmacokinetic interaction with other drugs must 
be acknowledged, the safest of them being escitalopram, 
citalopram and sertraline. Venlafaxine also represents a 
beneficial option in these situations. The anticholinergic 
effects of tricyclic antidepressants make them less appeal-
ing in neuro-oncological patients, although their sedative 
and antinociceptive potential can prove useful in some 
situations. Thanks to its dopaminergic-modulating action, 
bupropione can be helpful against symptoms of anergia 
and anhedonia; at high doses (>300mg) it tends to lower 
the seizure threshold, a particularly harmful effect in this 
population. Trazodone, at low doses – 50 to 100 mg – that 
are subtherapeutic in antidepressant terms, is beneficial in 
controlling insomnia.
Table 7. Antidepressants most widely used in oncology








Tricyclics Amitriptyline 25-50 50-150




Use of psychostimulants has been described as symp-
tomatic treatment of fatigue and asthenia. Methylphe-
nidate, at low doses (5 to 10 mg/day, as 2 split doses), 
can improve levels of attention and concentration, en-
ergy and cognitive function, and the effect is particularly 
rapid if compared with the more delayed effect of anti-
depressants. Insomnia, paranoid symptoms and halluci-
nations can occur, generally when these drugs are used 
at high doses. Use of psychostimulants in patients medi-
cated with procarbazine is contraindicated.
Benzodiazepines should be used with caution in this 
population, in situations of circumstantial anxiety or 
as coadjuvant therapy with antipsychotics when urgent 
sedation is required. Paradoxical effects have been re-
ported. Drugs with a short half-life that do not under-
go oxidative metabolism (e.g. lorazepam) should be 
preferred.
Psychotherapeutic interventions
Psychotherapy in neuro-oncological patients tends to be 
supportive, drawing on crisis intervention and psychoe-
ducational techniques 4 . Crisis intervention seeks to de-
velop coping in the context of specific, soluble problems; 
its goal is a possible return to previous psychological 
functioning, emphasising the importance of symptomatic 
control as an aid to adjustment. Often, the simple expres-
sion of interest on the part of the therapist can signifi-
cantly reduce distress in these patients. 
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Relaxation training and interventions of a cognitive-be-
havioural nature can be used where there is no significant 
cognitive compromise; they are potentially useful in con-
trolling common symptoms that have an impact on quality 
of life, such as headaches 4 . In patients with limitations in 
terms of concentration and memory, a therapeutic diary 
can be used. Sessions tend to be brief, so as not to tire the 
patient, and a diary provides a means of writing down the 
key ideas addressed so that they can be revisited later. 
Rehabilitation techniques have been developed to mitigate 
cognitive decline. In another dimension of intervention, 
non-verbal techniques, like music and other forms of artis-
tic expression, can enable patients to express themselves 
during phases of language compromise.
The bleak prognosis often inherent makes it relevant to 
tackle questions related to death and preparation for death. 
Expressing fears and desires frequently gives the patient 
relief from feelings of impotence and eases the inevitable 
burden of family members. 
Psychosocial impact on carers
Family members of patients with tumours of the CNS face 
adverse situations related to brain damage. Behavioural 
changes can give rise to conflicts and counter-reactions 
with carers. The frequent loss of autonomy in such pa-
tients, who need care and supervision, tends to be exhaust-
ing for carers, most commonly spouses and other direct 
family members. Communication can be compromised, 
making the most basic interaction frustrating for patient 
and family members alike. 
Taking these specificities into account, psychoeducation 
programmes have been developed for carers of patients 
with tumours of the CNS 19 . 
Provision of medical and nursing care to neuro-oncologi-
cal patients is complex, demanding and potentially prob-
lematic too. Healthcare professionals often have to deal 
with the death of their patients, and pathological reactions 
of loss are not uncommon 20 . Management of terminal 
care can be disturbing, and particularly therapeutic deci-
sions in patients who are confused or whose awareness is 
compromised.
Some practices have been presented as beneficial in mini-
mising the psychosocial impact on professionals. Exam-
ples are the practice of frequent rotations, particularly of 
nursing staff, and the existence of multidisciplinary sup-
port groups for professionals 21 .
Conclusion
Psychiatric symptoms may be the only manifestation of 
brain tumours. Because of the high degree of non-speci-
ficity of the symptomatology caused, such tumours may 
be confused at an early stage with so-called functional 
psychiatric disorders. Thus a careful clinical assessment 
associated with the presence of atypical characteristics 
at the time of presentation of symptomatology should 
prompt additional investigation, with recourse in partic-
ular to imaging examinations. Treatment of psychiatric 
symptoms is based on recourse to psychopharmaceuti-
cals, with antipsychotics at the top of the list, psychother-
apy and psychoeducation for carers.
Studying the symptomatology caused by tumours of the 
CNS may lead to a better understanding of the physio-
pathology of psychiatric disorders, categorisation of di-
agnoses and development of new and better forms of 
treatment. 
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